Addendum
Tislelizumab (NSCLC, second line or later) – Addendum to Project A24-128
Report documents
-
Addendum
Tislelizumab (NSCLC, ab Zweitlinie) Addendum zum Projekt A24-128 (Dossierbewertung)
Dossier assessment
Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior treatment with platinum-based chemotherapy; in addition, patients with epidermal growth factor receptor mutant or anaplastic lymphoma kinase positive NSCLC should also have received targeted therapies before receiving tislelizumab.
Additional information
Federal Joint Committee (G-BA)
18.06.2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-63
- Commission
- Commission awarded on 06.05.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-63_en
Connected Projects
-
Dossier assessment
Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V
Status: Commission completed